PMID- 30338813
OWN - NLM
STAT- MEDLINE
DCOM- 20191212
LR  - 20191217
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 22
IP  - 19
DP  - 2018 Oct
TI  - Research on changes in cognitive function, beta-amyloid peptide and neurotrophic 
      factor in stroke patients.
PG  - 6448-6455
LID - 16057 [pii]
LID - 10.26355/eurrev_201810_16057 [doi]
AB  - OBJECTIVE: To investigate the changes as well as the related mechanism in 
      cognitive function and levels of serum beta-amyloid peptide (Abeta) and brain-derived 
      neurotrophic factor (BDNF) in stroke patients. PATIENTS AND METHODS: A total of 
      30 patients with acute stroke treated in our hospital from June 2015 to September 
      2016 were selected as stroke group, while 30 volunteers during the same period 
      were enrolled as control group. Changes in cognitive function of patients were 
      evaluated using the Montreal Cognitive Assessment (MoCA) and mini-mental state 
      examination (MMSE) before and after the treatment. At the same time, the 
      concentrations of serum Abeta1-40 and BDNF were detected, and their correlations 
      with the MMSE score were analyzed. Finally, levels of serum cyclic adenosine 
      monophosphate (cAMP) and phosphorylated-cAMP-response element binding protein 
      (p-CREB), and the phosphorylation level of Tau protein were detected by Western 
      blotting. RESULTS: MoCA and MMSE scores of patients in stroke group were 
      significantly lower than those in control group (p < 0.01), and the scores were 
      significantly higher in stroke patients after treatment than those before 
      treatment (p < 0.01). Compared with those in control group, the serum Abeta1-40 
      concentration in patients in stroke group was significantly increased (p < 0.01), 
      but the BDNF level was significantly decreased (p < 0.01). Compared with those 
      before treatment, the serum Abeta1-40 concentration in patients was significantly 
      decreased after treatment (p < 0.01), but the BDNF concentration was 
      significantly increased (p < 0.01). Correlation analysis showed that the MMSE 
      score was negatively correlated with the concentration of Abeta1-40 (r2 = 0.764, p < 
      0.01), but positively related to the level of BDNF (r2 = 0.827, p < 0.01). 
      Compared with those in control group, the content of serum cAMP and p-CREB in 
      stroke patients was significantly decreased (p < 0.01), but the expression of 
      p-Tau was statistically increased (p < 0.01). CONCLUSIONS: The cognitive function 
      in stroke patients is impaired, with the rising content of serum Abeta1-40 and 
      reduction of BDNF, the mechanism of which is related to the decrease of cAMP and 
      p-CREB and the increase of p-Tau. This provides a theoretical basis for searching 
      the new therapeutic targets and new drugs for stroke.
FAU - Chen, H-G
AU  - Chen HG
AD  - Department of Neurosurgery, Yantai Yuhuangding Hospital, Yantai, Shandong 
      Province, China. guangqiangcui@163.com.
FAU - Wang, M
AU  - Wang M
FAU - Jiao, A-H
AU  - Jiao AH
FAU - Tang, G-T
AU  - Tang GT
FAU - Zhu, W
AU  - Zhu W
FAU - Zou, P
AU  - Zou P
FAU - Li, T
AU  - Li T
FAU - Cui, G-Q
AU  - Cui GQ
FAU - Gong, P-Y
AU  - Gong PY
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (CREB1 protein, human)
RN  - 0 (Cyclic AMP Response Element-Binding Protein)
RN  - 0 (MAPT protein, human)
RN  - 0 (Peptide Fragments)
RN  - 0 (amyloid beta-protein (1-40))
RN  - 0 (tau Proteins)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - E0399OZS9N (Cyclic AMP)
SB  - IM
MH  - Aged
MH  - Amyloid beta-Peptides/*blood
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Case-Control Studies
MH  - *Cognition
MH  - Cyclic AMP/blood
MH  - Cyclic AMP Response Element-Binding Protein/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*blood
MH  - Phosphorylation
MH  - Prognosis
MH  - Stroke/*blood/diagnosis/psychology/therapy
MH  - Time Factors
MH  - tau Proteins/blood
EDAT- 2018/10/20 06:00
MHDA- 2019/12/18 06:00
CRDT- 2018/10/20 06:00
PHST- 2018/10/20 06:00 [entrez]
PHST- 2018/10/20 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - 16057 [pii]
AID - 10.26355/eurrev_201810_16057 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6448-6455. doi: 
      10.26355/eurrev_201810_16057.